


Munich Cancer Registry



- ▶ Incidence and Mortality
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

ICD-10 C61: Prostate cancer

Survival

Year of diagnosis	1988-1997	1998-2019
Patients	7,431	59,132
Diseases	7,431	59,132
Cases evaluated	6,629	47,974
Creation date	01/27/2021	
Database export	01/07/2021	
Population (males)	2.43 m	



Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninstr. 15
Munich, 81377
Germany

<https://www.tumorregister-muenchen.de/en>

https://www.tumorregister-muenchen.de/en/facts/surv/sC61__E-ICD-10-C61-Prostate-cancer-survival.pdf

Index of figures and tables

Fig./Tbl.		Page
1a	Relative survival by period of diagnosis (chart)	3
1b	Survival by period of diagnosis (table)	3
1c	Relative survival by year of diagnosis (chart)	4
1d	Survival by year of diagnosis (table)	4
2a	Survival of total cohort (chart)	6
2b	Survival of total cohort (table)	6
3a	Observed survival by age category (chart)	7
3b	Relative survival by age category (chart)	7
3c	Survival by age category (table)	8
4a	Relative survival by TNM staging (chart)	9
4b	Survival by TNM staging (table)	9
4c	Conditional survival by extent of disease (chart)	11
4d	Conditional survival by extent of disease (table)	11
5a	Time to first progression (chart)	12
5b	Time to first progression (table)	12
5c	Observed post-progression survival (chart)	14
5d	Observed post-progression survival (table)	14
5e	Observed post-progression survival by period of progression (chart)	15
5f	Observed post-progression survival by period of progression (table)	15




Figure 1a. Relative survival of patients with prostate cancer by period of diagnosis. Included in the evaluation are 53,827 cases diagnosed between 1988 and 2019.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Period of diagnosis					
	1988-1997 n=6,619		1998-2006 n=18,799		2007+ n=28,409	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	94.5	99.2	96.0	99.4	95.9	98.9
2	88.3	97.3	92.0	98.7	91.8	97.7
3	82.4	95.3	88.0	97.7	87.5	96.2
4	77.2	93.8	84.2	96.9	84.0	95.5
5	72.4	92.3	80.5	96.2	80.3	94.5
6	68.1	91.1	77.1	95.6	76.9	93.9
7	63.7	89.5	73.5	94.7	73.5	93.3
8	59.6	88.1	70.1	94.1	69.9	92.3
9	56.0	87.1	66.7	93.3	66.9	92.1
10	52.3	85.5	63.1	92.3	63.9	91.8
11	48.9	84.2	59.5	91.0	60.8	91.5
12	45.7	83.0	56.3	90.2	57.7	91.0
13	42.3	81.2	53.1	89.4		
14	39.6	80.4	50.0	88.7		
15	37.2	80.0	47.4	88.6		
Median	10.6		14.0			

Table 1b. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by period of diagnosis for period 1988-2019 (N=53,827).




Figure 1c. Relative survival of patients with prostate cancer by year of diagnosis. Included in the evaluation are 47,208 cases diagnosed between 1998 and 2019.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2017, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

Years	Year of diagnosis													
	1998 n=1,255		1999 n=1,273		2000 n=1,401		2001 n=1,486		2002 n=2,699		2003 n=2,742		2004 n=2,713	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	92.1	96.0	95.3	99.1	96.6	100.2	95.0	98.4	96.1	99.6	96.8	100.1	97.2	100.3
2	87.7	95.2	90.5	97.9	92.3	99.4	91.0	97.8	92.2	99.1	93.3	99.8	93.5	99.6
3	82.8	93.6	85.2	95.7	88.0	98.4	86.8	96.8	88.2	98.2	89.9	99.4	89.3	98.4
4	78.5	92.4	79.5	92.9	83.9	97.6	83.4	96.4	84.3	97.4	86.6	99.1	86.4	98.4
5	73.9	90.7	76.0	92.4	79.6	96.3	79.8	95.9	81.4	97.5	82.6	98.0	82.8	97.7
6	69.8	89.2	72.0	91.1	76.0	95.7	77.0	96.1	77.3	96.1	79.3	97.6	79.5	97.3
7	66.0	87.9	68.7	90.4	72.6	95.0	73.3	95.2	73.4	94.9	75.6	96.7	76.4	97.1
8	62.7	87.3	64.9	88.9	69.3	94.5	69.2	93.7	69.6	93.7	72.4	96.4	73.2	96.6
9	58.8	85.5	61.5	87.8	65.7	93.6	65.6	92.7	66.2	92.9	68.9	95.5	69.9	96.1
10	55.1	83.7	57.5	85.9	61.9	92.2	63.0	93.0	62.9	92.1	65.0	94.2	66.7	95.7
11	52.0	82.8	54.2	84.6	58.3	90.7	59.5	91.8	59.7	91.5	60.7	92.0	62.8	94.3
12	49.3	82.2	51.4	84.0	54.4	88.7	56.7	91.8	56.9	91.4	57.6	91.4	59.3	93.2
13	46.6	81.8	48.5	83.2	51.1	87.6	52.7	89.7	54.0	91.1	54.5	91.0	55.8	92.0
14	43.3	80.1	46.0	83.0	48.1	86.8	50.0	89.6	50.8	90.2	51.0	89.6	52.3	90.8
15	40.6	79.0	44.1	84.0	46.1	87.7	46.8	88.6	47.6	89.3	48.0	89.0	50.3	92.0
Median	11.7		12.5		13.4		14.0		14.3		14.3		15.2	

<i>cont'd</i>	Year of diagnosis														
	2006 n=2,563		2007 n=3,026		2008 n=2,747		2009 n=2,542		2010 n=2,445		2011 n=2,611		2013 n=2,459		
	Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.7	98.8	96.1	99.1	96.3	99.3	96.1	99.1	96.1	99.1	96.0	99.0	96.1	99.1	
2	91.4	97.5	92.8	98.8	92.5	98.5	91.8	97.6	91.6	97.4	92.0	98.0	91.5	97.4	
3	87.5	96.6	88.4	97.4	88.5	97.3	87.1	95.6	87.9	96.6	88.0	96.9	86.8	95.4	
4	84.0	96.0	83.9	95.7	85.4	97.2	83.3	94.4	84.1	95.5	84.6	96.5	83.0	94.3	
5	80.4	95.2	80.4	94.9	81.2	95.8	79.9	93.7	79.9	94.0	81.5	96.3	79.4	93.4	
6	77.6	95.5	76.4	93.6	78.0	95.4	75.9	92.3	76.9	93.7	77.9	95.7	76.7	93.6	
7	73.5	94.0	72.9	92.7	74.4	94.6	72.8	91.7	73.2	92.7	74.7	95.3			
8	70.0	93.1	68.6	90.9	70.7	93.5	68.7	90.0	70.2	92.4	71.5	95.0			
9	66.8	92.7	65.2	90.0	67.2	92.7	66.3	90.4	67.9	93.2					
10	63.3	91.7	61.8	89.1	64.2	92.6	63.5	90.3							
11	59.8	90.9	58.3	87.8	61.6	93.1									
12	56.2	89.6	55.1	87.1											
13	53.5	89.9													
Median															

<i>cont'd</i>	Year of diagnosis												
	2014 n=2,448		2015 n=1,868		2016 n=1,803		2017 n=1,747		2018 n=1,465		2019 n=564		
	Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	96.3	99.3	95.5	98.5	93.9	96.7	95.4	98.3	96.5	99.3			
2	91.7	97.7	88.7	94.4	89.9	95.4	93.0	98.7					
3	87.5	96.3	83.4	91.8									
4	84.0	95.6	80.7	91.7									
5	80.7	95.1											
Median													

Table 1d. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by year of diagnosis for period 1998-2019 (N=47,208).




Figure 2a. Observed, expected and relative survival of the total cohort with prostate cancer. Included in the evaluation are 47,208 cases diagnosed between 1998 and 2019.

Years	Group	
	obs. %	rel. %
	All patients n=47,208	
0	100.0	100.0
1	96.0	99.1
2	91.9	98.1
3	87.7	96.8
4	84.0	96.1
5	80.4	95.2
6	77.0	94.6
7	73.5	93.9
8	70.0	93.1
9	66.7	92.6
10	63.3	91.7
11	59.9	90.7
12	56.6	89.9
13	53.4	89.1
14	50.3	88.4
15	47.6	88.3
Median	14.1	

Table 2b. Observed (obs.) and relative (rel.) survival of the total cohort with prostate cancer for period 1998-2019 (N=47,208).




Figure 3a. Observed survival of patients with prostate cancer by age category. Included in the evaluation are 47,208 cases diagnosed between 1998 and 2019.




Figure 3b. Relative survival of patients with prostate cancer by age category. Included in the evaluation are 47,208 cases diagnosed between 1998 and 2019.

Years	Age category							
	0-59 yrs n=6,473		60-69 yrs n=18,289		70-79 yrs n=17,698		80+ yrs n=4,748	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	98.5	99.3	98.0	99.7	95.7	99.4	85.6	95.4
2	96.7	98.1	95.7	99.1	91.3	98.8	73.3	91.5
3	94.9	97.2	93.3	98.5	86.3	97.6	62.2	87.8
4	93.0	96.1	90.9	98.1	82.0	97.4	53.2	85.4
5	91.5	95.5	88.7	97.8	77.3	96.7	45.2	83.5
6	90.0	95.0	86.5	97.8	73.0	96.7	37.5	80.6
7	88.6	94.6	84.2	97.7	68.3	96.2	30.8	78.3
8	87.1	94.2	81.9	97.8	63.4	95.7	24.7	75.2
9	85.8	94.0	79.8	98.3	58.6	95.2	19.5	72.5
10	84.3	93.7	77.1	98.2	53.7	94.7	15.6	71.8
11	82.4	93.1	74.4	98.2	48.6	93.9	12.0	69.9
12	80.3	92.4	71.9	98.8	43.7	93.4	9.0	67.5
13	78.6	92.2	69.1	99.2	38.9	93.0	6.7	67.1
14	77.2	92.4	66.2	99.5	34.4	92.7	5.0	68.2
15	75.8	92.8	63.3	100.2	30.9	95.1	3.5	67.0
Median			19.6		10.7		4.4	

Table 3c. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by age category for period 1998-2019 (N=47,208).




Figure 4a. Relative survival of patients with prostate cancer by TNM staging. For 38,398 of 47,208 cases diagnosed between 1998 and 2019 valid data could be obtained for this item. For a total of 38,319 cases an evaluable classification was established. The accumulated percentage exceeds the 100 % value because patients are potentially considered in more than one subgroup. The grey line represents the subgroup of 8,889 patients with missing values regarding TNM staging (18.8 % of 47,208 patients, the percent values of all other categories are related to n=38,319).

Years	TNM staging													
	T1 n=6,418		T2 n=19,207		T3 n=9,694		T4 n=1,328		N0 n=24,086		N+ n=3,226		NX n=5,571	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.9	100.0	98.9	101.2	98.0	100.5	86.6	89.9	99.2	101.4	94.4	96.7	94.4	98.4
2	92.1	100.3	97.6	102.4	95.3	100.3	72.1	77.6	98.2	102.8	87.0	91.4	89.2	96.9
3	87.7	100.0	95.9	103.2	92.0	99.5	62.1	69.1	96.8	103.9	80.6	86.9	83.6	94.9
4	83.7	99.9	94.2	104.2	88.7	98.7	53.4	61.5	95.3	104.9	74.5	82.6	78.8	93.4
5	79.2	99.3	92.1	104.9	85.2	97.7	46.5	55.5	93.3	105.6	69.0	78.7	74.2	92.1
6	74.9	98.8	90.1	105.7	82.0	97.0	41.3	51.0	91.2	106.4	64.6	75.9	70.2	91.3
7	70.5	98.0	87.9	106.5	78.7	96.3	37.6	48.0	89.1	107.3	60.4	73.3	65.6	89.5
8	65.5	96.3	85.6	107.3	75.5	95.7	34.6	46.0	86.8	108.0	56.4	70.9	61.2	87.9
9	61.7	96.1	83.2	108.1	72.0	94.8	31.9	43.9	84.4	108.8	52.3	68.1	57.2	86.4
10	56.8	93.9	80.6	108.8	68.2	93.3	29.3	42.1	81.7	109.3	48.9	66.0	52.7	84.1
Median	11.5				15.2		4.4				9.6		10.8	

<i>cont'd</i>	TNM staging			
	M1 n=3,115		NA/NOS n=8,889	
	obs. %	rel. %	obs. %	rel. %
Years				
0	100.0	100.0	100.0	100.0
1	78.6	81.9	92.6	97.3
2	58.3	63.1	85.3	94.4
3	43.3	48.7	77.7	90.5
4	33.4	39.0	71.1	87.5
5	26.2	31.8	65.2	84.9
6	21.2	26.8	59.4	82.0
7	17.6	23.2	53.4	78.1
8	14.9	20.6	47.4	73.9
9	13.3	19.0	42.3	70.3
10	10.9	16.5	37.7	67.1
Median	2.5		7.6	

Table 4b. Observed (obs.) and relative (rel.) survival of patients with prostate cancer by TNM staging for period 1998-2019 (N=38,319).




Figure 4c. Conditional relative 5-year survival of patients with prostate cancer by extent of disease. For 38,398 of 47,208 cases diagnosed between 1998 and 2019 valid data could be obtained for this item. For a total of 38,272 cases an evaluable classification was established. The grey line represents the subgroup of 8,936 patients with missing values regarding extent of disease (18.9 % of 47,208 patients, the percent values of all other categories are related to n=38,272).

Years	Extent of disease							
	Local		Regional		Distant		NA/NOS	
	n	Cond. surv. % 5 yrs	n	Cond. surv. % 5 yrs	n	Cond. surv. % 5 yrs	n	Cond. surv. % 5 yrs
0	32,813	103.7	2,344	92.7	3,115	31.8	8,936	84.9
1	30,500	103.3	2,168	90.0	2,334	32.9	7,766	84.9
2	28,800	102.7	1,980	88.9	1,610	37.2	6,854	84.0
3	26,886	102.6	1,759	87.7	1,097	42.9	5,949	83.5
4	25,041	102.5	1,534	87.1	773	49.8	5,239	82.9
5	23,096	102.3	1,308	87.6	550	53.3	4,519	82.4
6	20,980	102.1	1,115	86.0	399	58.9	3,819	80.0
7	18,769	102.1	949	85.9	295	62.1	3,100	79.6
8	16,673	102.3	784	85.0	223	59.1	2,415	79.8
9	14,719	102.3	633	86.5	173	53.1	1,879	79.6
10	12,845	103.5	521	86.3	125	58.4	1,508	80.3

Table 4d. Conditional relative 5-year survival of patients with prostate cancer by extent of disease for period 1998-2019 (N=38,272).

Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100 %) under the condition of being alive for a certain time period (x-axis in Figure 4a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 102.6% (n=26,886).




Figure 5a. Time to first progression of 46,872 patients with prostate cancer diagnosed between 1998 and 2019 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

		Type of progression						Distant metastasis (CI)
		Any type (CI)	Any type (1-KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)	
N	Events	43,779	43,779	46,871	46,871	46,872	46,872	43,782
compet.	Years	9,646	9,646	2,334	2,334	1,021	1,021	4,122
		8,632		15,038		15,689		10,424
		%	%	%	%	%	%	%
0		0.0	0.0	0.0	0.0	0.0	0.0	0.0
1		5.2	5.2	0.6	0.6	0.4	0.4	1.4
2		10.0	10.2	1.5	1.6	0.7	0.8	3.0
3		13.4	13.8	2.3	2.5	1.1	1.2	4.5
4		16.0	16.5	2.9	3.2	1.4	1.5	5.7
5		18.2	18.9	3.5	3.9	1.6	1.8	6.8
6		19.8	20.8	4.1	4.6	1.7	1.9	7.6
7		21.3	22.5	4.5	5.2	1.9	2.2	8.5
8		22.5	24.0	5.0	5.8	2.2	2.5	9.2
9		23.7	25.4	5.4	6.4	2.3	2.7	10.0
10		24.5	26.6	5.6	6.8	2.4	2.9	10.6
11		25.3	27.6	5.9	7.2	2.5	3.0	11.2
12		26.0	28.6	6.1	7.6	2.7	3.3	11.6
13		26.7	29.6	6.4	8.1	2.8	3.5	12.0
14		27.2	30.4	6.6	8.5	2.9	3.7	12.4
15		27.6	31.1	6.8	8.9	3.0	3.9	12.8

<i>cont'd</i>	Type of progression		
	Distant metast. (1-KM)	NOS (CI)	NOS (1-KM)
N	43,782	46,870	46,870
Events	4,122	4,982	4,982
compet.		13,854	
Years	%	%	%
0	0.0	0.0	0.0
1	1.4	3.0	3.0
2	3.1	5.6	5.8
3	4.6	7.1	7.5
4	5.9	8.4	8.9
5	7.2	9.3	10.1
6	8.1	10.1	11.0
7	9.1	10.7	11.8
8	10.0	11.1	12.4
9	11.0	11.5	13.0
10	11.9	11.9	13.5
11	12.6	12.2	14.0
12	13.2	12.4	14.4
13	13.9	12.7	14.8
14	14.5	12.8	15.1
15	15.2	12.9	15.3

Table 5b. Time to first progression of patients with prostate cancer for period 1998-2019 (N=46,872), also showing the total of progression events (Events) and of deaths as competing risk (compet.).




Figure 5c. Observed post-progression survival of 10,990 patients with prostate cancer diagnosed between 1998 and 2019. These 10,990 patients with documented progression events during their course of disease represent 23.4 % of the totally 46,872 evaluated cases (incl. M1, n=3,093, 6.6 %). Patients with cancer relapse documented via death certificates only were excluded (n=1,854, 4.0 %). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potentially considered in more than one subgroup.

Years	Type of progression				
	Any type n=10,990 %	Local relapse n=2,382 %	Lymph node n=1,036 %	Distant metastasis n=5,721 %	NOS n=4,344 %
0	100.0	100.0	100.0	100.0	100.0
1	84.8	84.0	87.3	73.8	93.1
2	73.0	73.6	79.4	55.1	87.1
3	64.1	66.2	71.7	41.3	82.5
4	57.2	59.7	64.0	32.3	77.6
5	51.9	55.8	57.0	26.0	73.1
6	47.5	52.5	52.8	21.4	68.7
7	43.8	48.7	48.3	18.0	64.5
8	40.6	45.5	41.9	15.4	61.2
9	37.7	43.0	38.3	13.5	57.1
10	34.8	40.5	31.6	11.4	53.4

Table 5d. Observed post-progression survival of patients with prostate cancer for period 1998-2019 (N=10,990).




Figure 5e. Observed post-progression (distant metastasis) survival of 6,863 patients with prostate cancer diagnosed between 1988 and 2019 by period of progression.

Years	Period of progression		
	1988-1997 n=740 %	1998-2006 n=1,634 %	2007+ n=4,489 %
0	100.0	100.0	100.0
1	66.8	69.6	74.0
2	43.2	48.9	55.7
3	29.3	33.4	42.8
4	19.2	25.3	33.8
5	14.4	19.7	27.7
6	11.2	16.2	22.8
7	7.4	13.4	19.5
8	6.4	11.0	16.7
9	4.6	9.7	14.6
10	3.4	8.1	12.3

Table 5f. Observed post-progression (distant metastasis) survival of patients with prostate cancer for period 1988-2019 by period of progression (N=6,863).

Shortcuts

MCR Munich Cancer Registry, Germany

NCI National Cancer Institute, USA

SEER Surveillance, Epidemiology, and End Results, USA

UICC Union for International Cancer Control, Geneva

DCO Death certificate only Death certificate provides the only notification to the registry.

NA Not available

NOS Not otherwise specified

OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate)
Date of entry: diagnosis
Event: death from any cause

RS Relative survival Survival compared to “general population”,
ratio of observed to expected survival (Ederer II method),
reflecting cancer specific survival

AS Assembled survival Assembled chart of
observed, expected, relative survival

CS Conditional survival Survival probability under the condition of surviving
a given period of time

TTP Time to progression Time to first progression / relapse
Date of entry: diagnosis
Event: (progression / relapse): first local-, lymph node recurrence,
distant metastasis or unspecified progression

1-KM 1 minus Kaplan-Meier estimator
 (“inverse” Kaplan-Meier estimator)

CI Cumulative incidence
Death as competing risk (according to Kalbfleisch und Prentice)

PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate)
Date of entry (progression / relapse): first local-, lymph node
recurrence, distant metastasis or unspecified progression
Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C61: Prostate cancer [Internet]. 2021 [updated 2021 Jan 27; cited 2021 Mar 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sC61__E-ICD-10-C61-Prostate-cancer-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.